{
  "deckTitle": "Customer Discovery — RangeFit",
  "slides": [
    {
      "type": "title",
      "title": "RangeFit — Safety‑Aware AI Coaching for Diabetes & PCOS/IR",
      "subtitle": "Media bubble shows diabetic athletes, CGM training tips, PCOS‑friendly strength, and IR‑friendly meals with strong engagement"
    },
    {
      "type": "table",
      "title": "Competitive Landscape Table (Condensed)",
      "headers": [
        "Competitor",
        "Niche",
        "Primary Gap"
      ],
      "rows": [
        [
          "Fitbod",
          "Strength planner",
          "No glucose/IR context"
        ],
        [
          "Freeletics",
          "AI coach",
          "Not diabetes‑aware"
        ],
        [
          "MySugr",
          "Diabetes logger",
          "No prescriptive training"
        ],
        [
          "Dexcom/LibreView",
          "Device ecosystem",
          "Not prescriptive"
        ],
        [
          "Supersapiens/Levels",
          "Metabolic insights",
          "Limited prescriptive workouts/strength"
        ]
      ],
      "notes": "Fitness excels at plans; diabetes/metabolic excels at data; neither delivers CGM/IR‑aware strength periodization"
    },
    {
      "type": "bullets",
      "title": "Content Audit Highlights",
      "bullets": [
        "Headline: Hooks and CTAs That Land (and Miss)",
        "Best examples (2–3): [Add links/screens]",
        "What worked: clear transformations, simple checklists, authentic voice",
        "What didn’t: generic nutrition claims, dense charts without action",
        "Takeaway: Short, specific, safety‑oriented tips outperform broad claims"
      ]
    },
    {
      "type": "bullets",
      "title": "Gap Analysis",
      "bullets": [
        "Headline: Underserved Segments + Weak Stages",
        "Underserved: T1D lifters; T2D adults; pre‑diabetics; women with PCOS/IR",
        "Weak stages: MOFU education on safety logic; BOFU proof/testimonials; Post‑purchase onboarding/community",
        "Takeaway: A safety‑aware, PCOS/IR‑friendly strength wedge is open"
      ]
    },
    {
      "type": "statement",
      "title": "Opportunity Statement",
      "text": "For active adults with diabetes or insulin resistance, we will provide safe, consistent progress by adapting workouts and low‑glycemic meals to daily glucose/metabolic context, unlike fitness apps that ignore glucose and tracking apps that stop at logging.",
      "notes": ""
    },
    {
      "type": "bullets",
      "title": "Brand Brief (Visual)",
      "bullets": [
        "Headline: Caregiver + Hero Archetype; Clear Outcomes",
        "Archetype/Positioning/Value prop: Safety‑aware strength and IR‑friendly meals; one plan/day; fewer scary episodes; steady energy",
        "Persuasion levers: Authority, Consistency, Unity, Reciprocity, Social Proof, Liking",
        "Differentiators: CGM‑aware periodization; PCOS/IR defaults; daily clarity with adaptive nudges"
      ]
    },
    {
      "type": "bullets",
      "title": "Persona (Profile)",
      "bullets": [
        "Headline: PCOS/IR “Maya” (32) — Sustainable Strength, Stable Energy",
        "Snapshot: Bio, JTBD, pains (energy dips, conflicting advice), gains (steady progress, confidence), proof needed (simple rules, success stories)",
        "Link: docs/discovery-output/personas-pcos.md"
      ]
    },
    {
      "type": "bullets",
      "title": "Customer Journey Map",
      "bullets": [
        "Headline: TOFU → MOFU → BOFU → Post",
        "TOFU: Shorts with sugar‑safe/PCOS‑friendly tips → CTA: free 7‑day plan",
        "MOFU: Lead magnet + 5‑email method explainer → CTA: 14‑day trial",
        "BOFU: Offer page with safety logic + testimonials → CTA: Start trial",
        "Post: Onboarding to daily plan; community challenges; non‑CGM path via manual logging/proxies (e.g., meal timing, RPE); Pro upsell when eligible",
        "Link: docs/discovery-output/journey.md"
      ]
    },
    {
      "type": "bullets",
      "title": "Success Metrics & KPIs",
      "bullets": [
        "Headline: 30/60/90 Targets Aligned to BRD",
        "Awareness: CTR to LP 2%/3%/4%",
        "Consideration: Opt‑ins 20%/25%/30%; email CTR 5%/8%/10%",
        "Conversion: LP CVR 6%/8%/10%; trial→paid 7%/9%/12%",
        "Post‑purchase: D1/D7/D30 near 55/30/15 (ambitious); plan adherence ≥ 60% (aspirational)",
        "Benchmarks context: email CTR ~2–5% (Salesforce); LP CVR ~5–6% (Landingi). Targets above medians are aspirational.",
        "Link: docs/discovery-output/kpis-30-60-90.md"
      ]
    },
    {
      "type": "bullets",
      "title": "Closing Takeaway",
      "bullets": [
        "Headline: Wedge First, Then Expand",
        "The bet: Win T1D lifter and PCOS/IR wedges with safety‑aware strength → expand into broader segments as integrations mature",
        "Next steps: Evidence capture, competitor cards, lead magnet build, tracking plan"
      ]
    },
    {
      "type": "bullets",
      "title": "Risks & Mitigations",
      "bullets": [
        "Regulatory ambiguity → wellness positioning; no clinical claims; disclaimers (include: “This product is not intended to diagnose, treat, cure, or prevent any disease.”)",
        "Device access → HealthKit/Google Fit first; apply to Dexcom/Abbott",
        "Privacy/security → SOC2 path; HIPAA‑aligned controls where appropriate"
      ]
    },
    {
      "type": "bullets",
      "title": "Experiment Backlog",
      "bullets": [
        "LP A/B (safety logic explainer)",
        "Lead magnet variants (T1D vs. PCOS)",
        "Email sequence tests (order, proof density)",
        "TOFU hooks (checklist vs. transformation)",
        "BRD: docs/brd.md",
        "Brand brief: docs/discovery-output/brand-brief.md",
        "Gap/opportunity: docs/discovery-output/gap-opportunity.md",
        "Journey: docs/discovery-output/journey.md",
        "KPIs: docs/discovery-output/kpis-30-60-90.md",
        "Personas: docs/discovery-output/personas-*.md",
        "Fitbod algorithm (no glucose/diabetes context): https://fitbod.me/blog/fitbod-algorithm/",
        "Freeletics official site (no diabetes/CGM features; accessed Oct 2025): https://www.freeletics.com/",
        "mySugr scope via diaTribe (logging/coaching, not exercise plans): https://diatribe.org/diabetes-technology/8-apps-improve-your-time-range",
        "Dexcom exercise tips (data/alerts guidance; not prescriptive plans): https://www.dexcom.com/en-us/all-access/managing-diabetes/exercise-tips-from-dietitian",
        "Supersapiens review (insights; not structured periodization): https://www.myprocoach.net/blog/supersapiens-review/",
        "GlucoseZone (exercise content; not CGM‑adaptive periodization): https://diatribe.org/diabetes-technology/glucosezone-exercise-app-people-diabetes",
        "CGM adoption (T2D; Mayberry 2023, JGIM): https://link.springer.com/article/10.1007/s11606-023-08222-3",
        "CGM adoption (T1D; T1D Exchange Registry 2025): https://t1dexchange.org/t1d-registry-technology-trends-2025/",
        "CGM adoption by age (T1D; 2022 T1DX-QI multicenter data, Diabetes supplement): https://diabetesjournals.org/diabetes/article/72/Supplement_1/1456-P/150825/1456-P-2022-State-of-Type-1-Diabetes-in-the-U-S",
        "2025 T1D Exchange figure reflects a registry sample; 2022 T1DX-QI data are EMR-based from 26 U.S. centers. Both show rising adoption with age disparities.",
        "Email CTR benchmarks (Salesforce): https://www.salesforce.com/marketing/email/benchmarks/",
        "Landing page conversion benchmarks (Landingi): https://landingi.com/landing-page/conversion-rate-a/",
        "App retention Day‑30 benchmarks (AppsFlyer via Sendbird): https://sendbird.com/blog/app-retention-benchmarks-broken-down-by-industry",
        "FDA enforcement example (Whoop warning letter; Arnold & Porter): https://www.arnoldporter.com/en/perspectives/advisories/2025/09/fda-warning-letter-to-fitness-wearable-sponsor",
        "Add direct link to “T1D Exchange – 2022 State of T1D in the US” CGM adoption figures."
      ]
    }
  ]
}